Clinical trial · Interventional
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
An Open Label Phase II Study for the Treatment of Liver Metastatic Colorectal Cancer and Non-Small Cell Lung Cancer With a Combination of TATE (Trans-Arterial Tirapazamine Embolization) and Pembrolizumab
NCT04701476CI-TRIAL-00108562recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer; Lung Cancer | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Regorafenib Pill | Drug | — | UNRESOLVED |
| TAS-102 pill | Drug | — | UNRESOLVED |
| TATE and pembrolizumab | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- colorectal cancer
- description
- metastatic colorectal cancer progressed on at least two lines of chemotherapy
- interventionNames
- Drug: TATE and pembrolizumab
- Drug: TAS-102 pill
- Drug: Regorafenib Pill
- type
- EXPERIMENTAL
- label
- NSCLC
- description
- Liver metastatic NSCLC progressed on immune checkpoint inhibitors and chemotherapy
- interventionNames
- Drug: TATE and pembrolizumab
Primary outcomes (2)
- measure
- Overall Survival for the mCRC cohort
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Liver metastatic MSS-mCRC or NSCLC without EGFR or AKT mutations * mCRC progressed on at least two lines of standard chemotherapy; or * NSCLC progressed on chemotherapy and an immune checkpoint inhibitor * Measurable disease * ECOG 0-1 * At least 4 weeks from prior chemotherapy and free from chemo-related toxicity * Adequate organ function Exclusion Criteria: * Prior organ transplantation * Liver metastasis more than 50% * Oxygen saturation less than 92% in room air * Prior autoimmune disorder * CNS metastasis * Major GI bleeding in the last 2 months
References
Publications (0)
Data not yet available
No reference posted for this study.